These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 19332671)

  • 1. Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
    Spyridaki I; Psaroulaki A; Vranakis I; Tselentis Y; Gikas A
    Antimicrob Agents Chemother; 2009 Jun; 53(6):2690-2. PubMed ID: 19332671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro susceptibility of Coxiella burnetii to linezolid in comparison with its susceptibilities to quinolones, doxycycline, and clarithromycin.
    Gikas A; Spyridaki I; Scoulica E; Psaroulaki A; Tselentis Y
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3276-8. PubMed ID: 11600400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro susceptibility of Coxiella burnetii to trovafloxacin in comparison with susceptibilities to pefloxacin, ciprofloxacin, ofloxacin, doxycycline, and clarithromycin.
    Gikas A; Spyridaki I; Psaroulaki A; Kofterithis D; Tselentis Y
    Antimicrob Agents Chemother; 1998 Oct; 42(10):2747-8. PubMed ID: 9756789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bacteriostatic and bactericidal activities of moxifloxacin against Coxiella burnetii.
    Rolain JM; Maurin M; Raoult D
    Antimicrob Agents Chemother; 2001 Jan; 45(1):301-2. PubMed ID: 11120982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro susceptibilities of spotted fever group rickettsiae and Coxiella burnetti to clarithromycin.
    Maurin M; Raoult D
    Antimicrob Agents Chemother; 1993 Dec; 37(12):2633-7. PubMed ID: 8109928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of rifapentine and other rifamycins against
    Miller HK; Kersh GJ
    Microbiol Spectr; 2024 Jul; 12(7):e0103424. PubMed ID: 38864598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of telithromycin against thirteen new isolates of C. burnetii including three resistant to doxycycline.
    Rolain JM; Lambert F; Raoult D
    Ann N Y Acad Sci; 2005 Dec; 1063():252-6. PubMed ID: 16481522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro susceptibility to tetracycline and fluoroquinolones of Japanese isolates of Coxiella burnetii.
    Andoh M; Naganawa T; Yamaguchi T; Fukushi H; Hirai K
    Microbiol Immunol; 2004; 48(9):661-4. PubMed ID: 15383702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro susceptibility of Coxiella burnetii to azithromycin, doxycycline, ciprofloxacin and a range of newer fluoroquinolones.
    Lever MS; Bewley KR; Dowsett B; Lloyd G
    Int J Antimicrob Agents; 2004 Aug; 24(2):194-6. PubMed ID: 15288324
    [No Abstract]   [Full Text] [Related]  

  • 10. Shell-vial assay: evaluation of a new technique for determining antibiotic susceptibility, tested in 13 isolates of Coxiella burnetii.
    Raoult D; Torres H; Drancourt M
    Antimicrob Agents Chemother; 1991 Oct; 35(10):2070-7. PubMed ID: 1759829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between ratio of serum doxycycline concentration to MIC and rapid decline of antibody levels during treatment of Q fever endocarditis.
    Rolain JM; Boulos A; Mallet MN; Raoult D
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2673-6. PubMed ID: 15980335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurotransmitter System-Targeting Drugs Antagonize Growth of the Q Fever Agent, Coxiella burnetii, in Human Cells.
    Fullerton MS; Colonne PM; Dragan AL; Brann KR; Kurten RC; Voth DE
    mSphere; 2021 Aug; 6(4):e0044221. PubMed ID: 34232075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pentamidine inhibits Coxiella burnetii growth and 23S rRNA intron splicing in vitro.
    Minnick MF; Hicks LD; Battisti JM; Raghavan R
    Int J Antimicrob Agents; 2010 Oct; 36(4):380-2. PubMed ID: 20599360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bacteriostatic and bactericidal activity of levofloxacin against Rickettsia rickettsii, Rickettsia conorii, 'Israeli spotted fever group rickettsia' and Coxiella burnetii.
    Maurin M; Raoult D
    J Antimicrob Chemother; 1997 Jun; 39(6):725-30. PubMed ID: 9222041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of axenic media to determine antibiotic efficacy against coxiella burnetii.
    Clay KA; Hartley MG; Russell P; Norville IH
    Int J Antimicrob Agents; 2018 May; 51(5):806-808. PubMed ID: 28802854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibiotic susceptibility determination for six strains of Coxiella burnetii MST 17 from Cayenne, French Guiana.
    Eldin C; Perreal C; Mahamat A; Djossou F; Edouard S; Raoult D
    Int J Antimicrob Agents; 2015 Nov; 46(5):600-2. PubMed ID: 26391379
    [No Abstract]   [Full Text] [Related]  

  • 17. Evaluation of Coxiella burnetii antibiotic susceptibilities by real-time PCR assay.
    Brennan RE; Samuel JE
    J Clin Microbiol; 2003 May; 41(5):1869-74. PubMed ID: 12734219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Q fever in the Greek island of Crete: detection, isolation, and molecular identification of eight strains of Coxiella burnetii from clinical samples.
    Spyridaki I; Gikas A; Kofteridis D; Psaroulaki A; Tselentis Y
    J Clin Microbiol; 1998 Jul; 36(7):2063-7. PubMed ID: 9650963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Effect of pH on Antibiotic Efficacy against Coxiella burnetii in Axenic Media.
    Smith CB; Evavold C; Kersh GJ
    Sci Rep; 2019 Dec; 9(1):18132. PubMed ID: 31792307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydroxychloroquine susceptibility determination of Coxiella burnetii in human embryonic lung (HEL) fibroblast cells.
    Angelakis E; Khalil JB; Le Bideau M; Perreal C; La Scola B; Raoult D
    Int J Antimicrob Agents; 2017 Jul; 50(1):106-109. PubMed ID: 28478211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.